Found: 8
Select item for more details and to access through your institution.
Comparison of phenotypic and genotypic tropism determination in triple-class-experienced HIV patients eligible for maraviroc treatment.
- Published in:
- Journal of Antimicrobial Chemotherapy (JAC), 2011, v. 66, n. 2, p. 265, doi. 10.1093/jac/dkq458
- By:
- Publication type:
- Article
Deep sequencing analysis of HIV-1 reverse transcriptase at baseline and time of failure in patients receiving rilpivirine in the phase III studies ECHO and THRIVE.
- Published in:
- Journal of Medical Virology, 2016, v. 88, n. 5, p. 798, doi. 10.1002/jmv.24395
- By:
- Publication type:
- Article
Long-term safety and efficacy of rilpivirine in combination with nucleoside/nucleotide reverse transcriptase inhibitors in HIV-1 infected patients: 336-week rollover study of phase 2b and 3 clinical studies.
- Published in:
- Antiviral Therapy, 2021, v. 26, n. 6-8, p. 95, doi. 10.1177/13596535211062388
- By:
- Publication type:
- Article
Compassionate use of long‐acting cabotegravir plus rilpivirine for people living with HIV‐1 in need of parenteral antiretroviral therapy.
- Published in:
- HIV Medicine, 2023, v. 24, n. 2, p. 202, doi. 10.1111/hiv.13370
- By:
- Publication type:
- Article
Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure.
- Published in:
- Clinical Infectious Diseases, 2023, v. 77, n. 10, p. 1423, doi. 10.1093/cid/ciad370
- By:
- Publication type:
- Article
Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study.
- Published in:
- Clinical Infectious Diseases, 2023, v. 76, n. 9, p. 1646, doi. 10.1093/cid/ciad020
- By:
- Publication type:
- Article
Simeprevir, daclatasvir, and sofosbuvir for hepatitis C virus-infected patients: Long-term follow-up results from the open-label, Phase II IMPACT study.
- Published in:
- Health Science Reports, 2020, v. 3, n. 2, p. 1, doi. 10.1002/hsr2.145
- By:
- Publication type:
- Article
HIV-1 V3 envelope deep sequencing forclinical plasma specimens failing inphenotypic tropism assays.
- Published in:
- AIDS Research & Therapy, 2010, v. 7, p. 4, doi. 10.1186/1742-6405-7-4
- By:
- Publication type:
- Article